All In Biotech

Drug Trial Radar · NCT02799069

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of a Nanoemulsion Gel Formulation BF-200 ALA, in Comparison With Metvix® and Placebo, for the Treatment of Actinic Keratosis With PDT

Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 571 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

571

Actual

Start

Apr 2008

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
Biofrontera Bioscience GmbHIndustry
Sponsor type
Industry
Collaborators
Accovion GmbH
First posted
Jun 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.

Conditions

  • Actinic Keratosis

Interventions

  • BF-200 ALADrug

    topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.

  • MAL CreamDrug

    topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.

  • VehicleDrug

    topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), ITTTime frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment
  2. Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), PPTime frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment
  3. Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT) Illuminated With Narrow Spectrum Devices OnlyTime frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.